New Publication Validates Palvella's QTORIN™ Approach for Challenging Lymphatic Malformations
PVLA has more than doubled off its 52-week low of $18.225.
Summary
Palvella Therapeutics announced the publication of a comprehensive review article in the Journal of Vascular Anomalies, detailing the infiltrative growth and therapeutic challenges of microcystic lymphatic malformations (LMs). The publication highlights the significant unmet medical need for this condition, for which there are no FDA-approved therapies, and reinforces the scientific rationale for Palvella's QTORIN™ rapamycin as a potential targeted treatment. This news follows the company's recent announcement on March 27th of positive Phase 3 SELVA study results for QTORIN™ in microcystic LMs. The scientific validation from this publication strengthens the commercial and clinical positioning of QTORIN™, adding credibility to the company's lead product and its development strategy. Investors should monitor upcoming regulatory submissions and commercialization efforts for QTORIN™.
At the time of this announcement, PVLA was trading at $112.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.23 to $151.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.